• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Asthma COPD Drugs Market

    ID: MRFR/Pharma/7277-CR
    149 Pages
    Rahul Gotadki
    July 2025

    Asthma and COPD Drugs Market Research Report By Drug Class (Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers), By Route of Administration (Inhalation, Oral, Injection, Nasal), By Application (Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Pulmonary Hypertension), By Patient Group (Adult, Pediatric, Geriatric) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Asthma COPD Drugs Market Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Asthma COPD Drugs Market Summary

    As per Market Research Future Analysis, the Asthma and COPD Drugs Market was valued at 34.26 USD Billion in 2023 and is projected to reach 50 USD Billion by 2035, reflecting a CAGR of 3.2% from 2025 to 2035. The market is driven by the rising incidence of respiratory diseases, advancements in drug delivery technologies, and growing awareness initiatives.

    Key Market Trends & Highlights

    The market for asthma and COPD medications is evolving with significant trends.

    • Over 300 million people globally are diagnosed with asthma, and approximately 251 million are affected by COPD.
    • Bronchodilators are expected to grow from 10.0 USD Billion in 2024 to 13.5 USD Billion by 2035.
    • The North America region is projected to hold a majority share valued at 16.77 USD Billion in 2024.
    • The demand for combination drugs is anticipated to rise from 10.5 USD Billion in 2024 to 14.5 USD Billion by 2035.

    Market Size & Forecast

    2023 Market Size USD 34.26 Billion
    2024 Market Size USD 35.35 Billion
    2035 Market Size USD 50 Billion
    CAGR (2025-2035) 3.2%

    Major Players

    Key players include Merck and Co, Pfizer, AstraZeneca, GlaxoSmithKline, and Boehringer Ingelheim.

    Asthma COPD Drugs Market Trends

    In the Asthma and COPD Drugs Market, North America held the largest market share valued at 15.0 USD billion in 2024.

    The asthma and COPD drugs market in Europe is expected to be valued at 12.5 USD billion by 2035 The bronchodilators segment was valued at 12.5 USD billion in the asthma and COPD drugs market in 2024. The market value for corticosteroids is projected to reach 14.5 USD billion by 2035. Advancements in drug development and innovation is opening avenues for growth in the Asthma and COPD Drugs Market.

    Major Players

    Key players in the Asthma and COPD Drugs Market include Novartis, Vertex Pharmaceuticals, Teva Pharmaceutical Industries, and other players.

    Market Size, Forecast and Growth Rate

    2024 Market Size: USD 35.35 billion

    2035 Market Size: USD 50 billion

    CAGR 2025 to 2035: 3.2%

    Largest Regional Market Share in 2024: North America

    Key Asthma and COPD Drugs Market Trends Highlighted

    The global asthma and COPD medications market is expanding rapidly as the prevalence of respiratory disorders rises and people become more aware of treatment alternatives. The aging population, which is more prone to chronic respiratory diseases, is a major market driver.

    Furthermore, advances in medication formulations and inhalation technology improve the efficacy and ease of medicines, making them more appealing to both healthcare practitioners and patients. There is a rising emphasis on customized medicine, with treatments tailored to specific patient needs, reflecting the market's shift toward precision therapeutics.

    Opportunities to be explored in this market include the expansion of telemedicine and digital health solutions, allowing for improved patient monitoring and management of asthma and COPD. The integration of artificial intelligence in healthcare can further enhance treatment outcomes by providing data-driven insights for clinicians. 

    Additionally, an increasing focus on preventive care and early diagnosis presents avenues for pharmaceutical companies to develop innovative drugs that cater to unmet needs, especially in emerging markets. 

    In recent times, regulatory bodies are emphasizing the approval of novel therapies and biologics, which is shaping the competitive landscape of the market. Collaborative efforts between public and private sectors are fostering research and development initiatives, allowing companies to innovate and bring forward new treatment modalities. 

    Furthermore, global campaigns promoting respiratory health awareness are expected to elevate demand for effective treatments. These trends indicate a dynamic market environment that is rapidly adapting to meet the needs of patients suffering from asthma and COPD on a global scale.

    The ongoing evolution of therapeutic options for asthma and COPD reflects a concerted effort to enhance patient outcomes and address the multifaceted nature of these respiratory conditions.

    U.S. Food and Drug Administration (FDA)

    Asthma COPD Drugs Market Drivers

    Market Growth Projections

    The Global Asthma and COPD Drugs Market Industry is poised for substantial growth, with projections indicating a market value of 35.4 USD Billion in 2024 and an anticipated increase to 50 USD Billion by 2035. This growth trajectory reflects a compound annual growth rate (CAGR) of 3.2% from 2025 to 2035. Factors contributing to this expansion include rising prevalence rates, advancements in drug development, and increased awareness of respiratory diseases. As the market evolves, it is essential to monitor these trends to understand their implications for stakeholders in the asthma and COPD therapeutic landscape.

    Growing Geriatric Population

    The aging population worldwide significantly influences the Global Asthma and COPD Drugs Market Industry. Older adults are at a higher risk for developing respiratory diseases due to age-related physiological changes and comorbidities. As the global population aged 65 and older continues to rise, the demand for effective asthma and COPD treatments is likely to increase. This demographic shift underscores the need for tailored therapeutic approaches that address the unique challenges faced by elderly patients. Consequently, the market is projected to grow at a CAGR of 3.2% from 2025 to 2035, reflecting the increasing need for specialized care.

    Advancements in Drug Development

    Innovations in drug formulation and delivery systems are pivotal in shaping the Global Asthma and COPD Drugs Market Industry. Recent advancements include the development of biologics and targeted therapies that offer improved efficacy and safety profiles. For instance, monoclonal antibodies have emerged as effective treatments for severe asthma, enhancing patient outcomes. These advancements not only address unmet medical needs but also stimulate market growth. The continuous evolution of inhaler technologies, such as smart inhalers, further supports adherence and management of these chronic conditions, potentially increasing the market's value significantly over the next decade.

    Increased Awareness and Education

    Enhanced awareness and education regarding asthma and COPD are vital drivers of the Global Asthma and COPD Drugs Market Industry. Public health campaigns and educational programs have significantly improved understanding of these diseases, leading to earlier diagnosis and treatment. This increased awareness encourages patients to seek medical advice and adhere to prescribed therapies, thereby boosting the demand for asthma and COPD medications. As healthcare providers emphasize the importance of disease management, the market is likely to experience sustained growth, aligning with the projected increase in market value to 35.4 USD Billion in 2024.

    Government Initiatives and Funding

    Government initiatives aimed at improving respiratory health play a crucial role in the Global Asthma and COPD Drugs Market Industry. Various countries have implemented national programs to enhance awareness, prevention, and treatment of asthma and COPD. For example, funding for research and development of new therapies is often provided through public health initiatives. Such support is essential for fostering innovation in drug development and ensuring access to effective treatments for patients. As a result, the market is expected to benefit from increased investments, contributing to its growth trajectory towards 50 USD Billion by 2035.

    Rising Prevalence of Respiratory Diseases

    The increasing incidence of asthma and chronic obstructive pulmonary disease (COPD) globally drives the Global Asthma and COPD Drugs Market Industry. According to health statistics, approximately 300 million people worldwide suffer from asthma, while COPD affects around 251 million individuals. This growing patient population necessitates effective treatment options, thereby expanding the market for asthma and COPD medications. As awareness of these conditions rises, the demand for innovative therapies is likely to increase, contributing to the market's projected growth to 35.4 USD Billion in 2024 and 50 USD Billion by 2035.

    Market Segment Insights

    Asthma and COPD Drugs Market Drug Class Insights

    The Asthma and COPD Drugs Market, under the drug class segment, exhibits a robust structure with key categories including bronchodilators, corticosteroids, combination drugs, and leukotriene modifiers. In 2024, bronchodilators held a majority share valued at 12.5 USD billion and are projected to continue their dominance, reaching 18.0 USD billion by 2035. This class is essential as it provides immediate relief of airway obstruction, making it pivotal for patients with asthma and chronic obstructive pulmonary disease (COPD).

    Corticosteroids come next, valued at 10.0 USD billion in 2024 and anticipated to grow to 14.5 USD billion in 2035; they play a crucial role by reducing inflammation, further outlining their importance in managing chronic conditions. Combination drugs, valued at 8.85 USD billion in 2024 and increasing to 12.5 USD billion by 2035, are significant as they offer a synergistic effect that enhances treatment efficacy by addressing both bronchoconstriction and inflammation simultaneously.

    Leukotriene modifiers, with a valuation of 3.0 USD billion in 2024 and expected to rise to 5.0 USD billion by 2035, are important for their role in blocking specific pathways involved in asthma and allergy responses, although they represent the smallest segment of the market.

    The comprehensive Asthma and COPD Drugs Market data showcases the dynamic interplay among these drug classes, highlighting their respective contributions to alleviating the symptoms of patients suffering from asthma and COPD, which collectively underscored the opportunities for growth and innovation in medication development within this industry.

    Market data for asthma and COPD medications illustrates the intricate relationships among these drug categories, emphasizing their individual roles in alleviating symptoms for patients with asthma and COPD, thereby underscoring the potential for growth and innovation in pharmaceutical development within this sector.

    Asthma and COPD Drugs Market Route of Administration Insights

    The Asthma and COPD Drugs Market is witnessing significant developments driven by the various routes of administration available for the treatment of these respiratory conditions. The inhalation route is a dominant approach due to its effectiveness in delivering medication directly to the lungs, offering quick relief and better patient compliance. 

    The oral route is also notable for its convenience, providing an alternative for patients who may have difficulty using inhalers, thereby expanding the accessibility of treatments.

    Injection methods, though less common, are essential for delivering biologic therapies, particularly for more severe cases, while nasal administration presents a promising option for systemic delivery with rapid onset of action. Each route caters to specific patient needs, reflecting diverse treatment preferences and enhancing overall patient adherence.

    Asthma and COPD Drugs Market Application Insights

    The Asthma and COPD Drugs Market comprises various applications including asthma, chronic obstructive pulmonary disease, allergic rhinitis, and pulmonary hypertension, each playing a crucial role in defining market dynamics. Asthma treatments, especially, are pivotal as they cater to a broad demographic, reflecting the disease's prevalence globally. Chronic obstructive pulmonary disease dominates the market due to its increasing incidence, emphasizing the necessity for effective therapies.

    Allergic rhinitis treatments cater to millions suffering worldwide, driving consistent demand. The market is also supported by advancements in drug formulations and an increasing reliance on innovative therapies to manage these conditions. However, challenges such as high treatment costs and regulatory barriers could hinder growth. 

    Nevertheless, the ongoing research and development efforts within the industry highlight promising opportunities, aiming to enhance the Asthma and COPD Drugs Market revenue in the coming years.

    Asthma and COPD Drugs Market Patient Group Insights

    The Asthma and COPD Drugs Market by patient groups include adults, pediatrics, and the geriatric population. Pediatrics is increasingly recognized in the Asthma and COPD Drugs Market, as early intervention in childhood asthma and related conditions can lead to better outcomes and management as they grow.

    The geriatric segment is gaining importance due to the rising prevalence of age-related respiratory issues, which necessitates tailored drug therapies and increased healthcare focus. Trends show a growing demand for innovative therapies catering to these diverse patient groups, while opportunities arise in personalized medicine and digital health solutions targeting asthma and COPD management.

    The Asthma and COPD Drugs Market segmentation reflects a significant growth potential, aligning with increasing healthcare investments and a heightened global focus on respiratory health. This market is influenced by growth drivers such as rising pollution levels and lifestyle changes affecting respiratory health across different age demographics.

    Get more detailed insights about Asthma and COPD Drugs Market Research Report - Forecast to 2035

    Regional Insights

    In 2024, North America holds a dominant position with an impressive valuation of 15.0 USD billion, projected to increase to 20.0 USD billion by 2035, primarily due to advanced healthcare infrastructure and increased prevalence of respiratory diseases. Europe follows closely, valued at 10.5 USD billion in 2024 and expected to grow to 12.5 USD billion, reflecting robust investments in healthcare and Research and Development initiatives.

    Asia Pacific generated a notable valuation of 5.0 USD billion in 2024, anticipated to grow to 9.0 USD billion, fueled by rising awareness and access to medical services in developing nations. South America, valued at 3.0 USD billion in 2024 and rising to 4.0 USD billion, faces challenges in healthcare access but is progressively expanding its market share. The Middle East and Africa represents a smaller segment at 1.85 USD billion in 2024, likely to reach 4.5 USD billion by 2035, influenced by population growth and an increasing focus on healthcare improvements.

    Asthma and COPD Drugs Market Regional Insights

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Key Players and Competitive Insights

    The Asthma and COPD Drugs Market is characterized by a robust competitive landscape driven by the growing prevalence of respiratory diseases and increasing awareness regarding their management. Leading pharmaceutical companies are focused on enhancing their product offerings and expanding their market reach to address the diverse needs of patients.

    The market is increasingly characterized by innovation, with companies investing heavily in research and development to bring forth novel therapies and treatment options. The competitive dynamics are further shaped by factors such as regulatory frameworks, pricing strategies, and collaborations among key players in the industry. Companies that can effectively navigate these challenges are likely to maintain a strong presence in the market.

    Novartis has established a robust position in the global market for asthma and COPD medications by leveraging innovative therapies and forming strategic alliances. The portfolio features notable treatments like Ultibro Breezhaler and Seebri Breezhaler, focusing on essential elements of chronic respiratory diseases. Furthermore, the partnership with Roche regarding Xolair continues to influence the severe asthma market.

    Supported by a robust research pipeline and an extensive global presence, Novartis is actively seeking opportunities to enhance respiratory care, while also expanding its focus into wider biopharmaceutical sectors. Its dedication to enhancing patient access and adapting to changing treatment requirements solidifies its status as a significant entity in the asthma and COPD pharmaceutical arena.

    Chiesi Farmaceutici has established a significant presence in the global asthma and COPD pharmaceuticals market, particularly through its emphasis on inhalation therapies and fixed-dose combination treatments. Chiesi is recognized for its dedication to tackling respiratory diseases, with key products like Foster and Trimbow being extensively utilized to effectively manage chronic asthma and COPD symptoms.

    The organization has achieved significant advancements in increasing its market presence through strategic innovation and global expansion, enabling it to serve a diverse patient demographic across Europe, Asia, and developing markets. Chiesi demonstrates a strong dedication to research and development, especially in formulation science and delivery devices, which guarantees a consistent flow of innovative respiratory therapies. 

    Furthermore, the organization highlights solutions that prioritize patients and promotes sustainable healthcare practices, thereby enhancing its global standing in the asthma and COPD pharmaceuticals sector.

    Key Companies in the Asthma COPD Drugs Market market include

    Industry Developments

    • Q2 2024: FDA approves Sanofi and Regeneron's Dupixent as first biologic for COPD The US Food and Drug Administration approved Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD), marking the first biologic therapy for this indication and addressing a major unmet need for patients with type 2 inflammation.
    • Q2 2024: Sanofi and Regeneron announce FDA approval of Dupixent for COPD Sanofi and Regeneron received FDA approval for Dupixent to treat COPD with type 2 inflammation, following positive Phase III trial results showing reduced exacerbations and improved lung function.
    • Q2 2024: Sanofi and Regeneron’s Dupixent receives EMA approval for COPD The European Medicines Agency approved Dupixent for COPD, expanding its use beyond severe asthma and marking a significant development in biologic therapies for respiratory diseases.
    • Q2 2024: AstraZeneca launches Airsupra inhaler for asthma in US market AstraZeneca announced the commercial launch of Airsupra, a new inhaler for asthma, in the United States, aiming to improve patient outcomes with a novel dual-action mechanism.
    • Q3 2024: GSK receives FDA approval for Trelegy Ellipta expanded COPD indication GlaxoSmithKline (GSK) secured FDA approval to expand the indication of Trelegy Ellipta, its triple therapy inhaler, for use in a broader COPD patient population.
    • Q3 2024: GSK opens new respiratory drug manufacturing facility in North Carolina GSK inaugurated a new manufacturing facility dedicated to respiratory drugs, including asthma and COPD treatments, to meet growing demand in the US market.
    • Q2 2024: AstraZeneca partners with Honeywell to develop smart inhalers for asthma and COPD AstraZeneca announced a partnership with Honeywell to co-develop smart inhalers equipped with digital monitoring for asthma and COPD patients, aiming to improve medication adherence and outcomes.
    • Q1 2025: Novartis appoints new Head of Respiratory Division Novartis named Dr. Maria Lopez as the new Head of its Respiratory Division, overseeing the company's asthma and COPD drug portfolio and strategic direction.
    • Q2 2025: Pfizer acquires biotech startup Respira Therapeutics for $350M Pfizer completed the acquisition of Respira Therapeutics, a biotech firm specializing in inhaled therapies for asthma and COPD, to strengthen its respiratory drug pipeline.
    • Q2 2025: Chiesi secures FDA approval for new triple therapy inhaler for COPD Chiesi Farmaceutici received FDA approval for its new triple therapy inhaler targeting COPD, expanding treatment options for patients with moderate to severe disease.
    • Q1 2025: AstraZeneca wins $200M contract to supply Symbicort to US Department of Veterans Affairs AstraZeneca was awarded a $200 million contract to supply its Symbicort inhaler for asthma and COPD to the US Department of Veterans Affairs, ensuring access for veterans nationwide.
    • Q2 2024: FDA approves Nucala for severe asthma; COPD indication expected Q3 2025 The FDA approved Nucala (mepolizumab) for severe asthma, with a COPD indication anticipated in Q3 2025, expanding the drug's reach in respiratory care.

    Future Outlook

    Asthma COPD Drugs Market Future Outlook

    The Asthma and COPD Drugs Market is projected to grow at a 3.2% CAGR from 2024 to 2035, driven by increasing prevalence and advancements in drug formulations.

    New opportunities lie in:

    • Invest in personalized medicine to enhance treatment efficacy for diverse patient populations.
    • Develop digital health solutions to improve patient adherence and monitoring.
    • Explore emerging markets with rising asthma and COPD incidences for expansion opportunities.

    By 2035, the market is expected to exhibit robust growth, reflecting evolving treatment paradigms and increased patient access.

    Market Segmentation

    Asthma and COPD Drugs Market Regional Outlook

    • North America
    • Europe
    • South America
    • Asia Pacific
    • Middle East and Africa

    Asthma and COPD Drugs Market Drug Class Outlook

    • Bronchodilators
    • Corticosteroids
    • Combination Drugs
    • Leukotriene Modifiers

    Asthma and COPD Drugs Market Application Outlook

    • Asthma
    • Chronic Obstructive Pulmonary Disease
    • Allergic Rhinitis
    • Pulmonary Hypertension

    Asthma and COPD Drugs Market Patient Group Outlook

    • Adult
    • Pediatric
    • Geriatric

    Asthma and COPD Drugs Market Route of Administration Outlook

    • Inhalation
    • Oral
    • Injection
    • Nasal

    Report Scope

    Report Attribute/Metric

    Details

    Market Size 2023

    34.26 (USD billion)

    Market Size 2024

    35.35 (USD billion)

    Market Size 2035

    50.0 (USD billion)

    Compound Annual Growth Rate (CAGR)

    3.2% (2025-2035)

    Report Coverage

    Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

    Base Year

    2024

    Market Forecast Period

    2025-2035

    Historical Data

    2019-2024

    Market Forecast Units

    USD billion

    Key Companies Profiled

    Novartis, Vertex Pharmaceuticals, Teva Pharmaceutical Industries, Mylan, Boehringer Ingelheim, Pfizer, Johnson & Johnson, Merck & Co, AstraZeneca, Chiesi Farmaceutici, Eli Lilly, Sanofi, GlaxoSmithKline, Roche, AbbVie

    Segments Covered

    Drug Class, Route of Administration, Application, Patient Group, Regional

    Key Market Opportunities

    Emerging biologics and biosimilars, Digital health solutions integration, Increased prevalence and awareness, Advancements in personalized medicine, Growth in elderly population.

    Key Market Dynamics

    Rising prevalence of respiratory diseases, Growing aging population, Advancements in drug formulations, Increased healthcare expenditure, Launch of biosimilars and generics

    Countries Covered

    North America, Europe, APAC, South America, MEA

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What was value of the Asthma and COPD Drugs Market in 2024?

    The Asthma and COPD Drugs Market was valued at 35.35 USD billion in 2024.

    What will be the value of the Asthma and COPD Drugs Market by 2035?

    By 2035, the Asthma and COPD Drugs Market is projected to reach 50.0 USD billion.

    What is the expected CAGR for the Asthma and COPD Drugs Market from 2025 to 2035?

    The expected CAGR for the Asthma and COPD Drugs Market from 2025 to 2035 is 3.2%.

    Which region dominated the Asthma and COPD Drugs Market in 2024?

    North America dominated the Asthma and COPD Drugs Market with a value of 15.0 USD billion in 2024.

    What will the value for Europe be in the Asthma and COPD Drugs Market by 2035?

    Europe is expected to reach 12.5 USD billion in the Asthma and COPD Drugs Market by 2035.

    What was the value of the Bronchodilators segment in the Asthma and COPD Drugs Market for 2024?

    The bronchodilators segment was valued at 12.5 USD billion in the Asthma and COPD Drugs Market in 2024.

    Who are the key players in the Asthma and COPD Drugs Market?

    Key players in the market include Novartis, Teva Pharmaceutical Industries, and AstraZeneca, among others.

    What is the projected value of Combination Asthma and COPD Drugs in 2035?

    Combination asthma and COPD drugs are expected to total 12.5 USD billion by 2035.

    How much value did Leukotriene Modifiers generate in the Asthma and COPD Drugs Market in 2024?

    The leukotriene modifiers segment totaled 3.0 USD billion in 2024 in the Asthma and COPD Drugs Market.

    What market value is projected for the Asia Pacific Asthma and COPD Drugs in 2035?

    Asia Pacific is projected to reach 9.0 USD billion in the Asthma and COPD Drugs Market by 2035.

    Asthma and COPD Drugs Market Research Report - Forecast to 2035 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Stories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study
    Chemicals and Materials